Pliant Sees Treating Fibrosis As Primary Goal, Not Add-On
This article was originally published in Start Up
Executive Summary
The start-up will advance UCSF research on fibrosis to improve upon current treatments for idiopathic pulmonary fibrosis, and possibly create therapeutics for fibrosis of the liver, kidneys and GI tract as well.